AskBio announced that the first participant has been randomised in Europe in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II clinical trial of AB-1002 for the treatment of congestive heart failure (CHF). 

GenePHIT is an adaptive, double-blind, placebo-controlled, randomised, multicentre trial to evaluate the safety and efficacy of a single intracoronary infusion of AB-1002 in adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms who have been medically stable for at least four weeks. 

GenePHIT will include between 90 and 150 adults with heart failure with reduced ejection fraction (HFrEF) between 15 and 35% who continue to suffer from symptoms despite guideline-recommended therapy.  

The study is enrolling participants across clinical centres in the United States and Europe (Austria, Germany, Hungary, Netherlands, Spain, UK). 

“Cardiovascular disease is the most common cause of death in Europe, claiming nearly four million lives each year, and it accounts for 45% of all deaths in females and 39% of all deaths in males,” said Timothy Henry, GenePHIT Principal Investigator and Steering Committee Member. “As society ages, the burden heart failure places on individuals and healthcare systems will only increase unless a solution is found.” 

AB-1002 is an investigational gene therapy that has been approved for experimental clinical trials only and has not been approved by any regulatory authority, and its efficacy and safety have not been established or fully evaluated. 

“The potential of gene therapy to address the intracellular abnormalities that characterise heart failure is immense, and we are excited to have achieved this critical milestone for the GenePHIT study in Europe,” said Canwen Jiang, Chief Development Officer and Chief Medical Officer, AskBio.

Diana Spencer, Senior Digital Content Editor, DDW